Get the Stockscreener App
128.97
0.46%
-0.59
Pre-market:
128.62
-0.35
-0.27%
Illumina Inc stock is traded at $128.97, with a volume of 1.31M.
It is down -0.46% in the last 24 hours and down -3.89% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$129.56
Open:
$130.895
24h Volume:
1.31M
Relative Volume:
0.66
Market Cap:
$19.72B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
28.89
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
+5.83%
1M Performance:
-3.89%
6M Performance:
+32.03%
1Y Performance:
+51.93%
1-Day Range:
$128.60
$132.28
1-Week Range:
$118.53
$134.76
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
128.97 | 19.81B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
512.69 | 190.90B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
204.73 | 144.26B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
648.70 | 50.60B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.54 | 33.67B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.04 | 30.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Genomics Services Market Projected to Surpass USD 25.18 Billion by 2035; Increasing Genetic Disorders’ Prevalence is Driving Market Growth Globally – SNS Insider - GlobeNewswire Inc.
ARK Investment Management Boosts Stake in Illumina - National Today
ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN - MarketBeat
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term - Nasdaq
DNA Microarray Market is expected to reach US$ 6.12 billion - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ILMN: Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook - TradingView
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - TradingView
ILMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN - MarketBeat
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus
Illumina, Inc. (ILMN) Stock Analysis: Exploring The Upside With A 33% Return On Equity - DirectorsTalk Interviews
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing - Yahoo Finance
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating - TipRanks
Andra AP fonden Buys 58,209 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Position Boosted by Citigroup Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsPR Newswire APAC - PR Newswire Asia
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina
Illumina, Inc. Whole-Genome Sequencing Technology to Accelerate Rare Disease Testing in Florida - marketscreener.com
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. Unveils Revolutionary Genomic Advancements - Devdiscourse
[PRNewswire] Illumina Launches TruPath Genome - Yonhap News Agency
The next generation is shaping the future of rare diseases - Illumina
Evercore ISI reiterates Illumina stock rating on competitive positioning - Investing.com
Evercore ISI reiterates Illumina stock rating on competitive positioning By Investing.com - Investing.com India
Canaccord reiterates Illumina stock Hold rating after Roche pricing By Investing.com - Investing.com Canada
Canaccord reiterates Illumina stock Hold rating after Roche pricing - Investing.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Present - PharmiWeb.com
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026 - Yahoo Finance
Illumina partners go beyond the genome, driving cancer breakthroughs - marketscreener.com
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics - PR Newswire
Vestmark Advisory Solutions Inc. Sells 22,703 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Shares Bought by North Star Asset Management Inc. - MarketBeat
Illumina Genome Push Raises Questions On Growth, Adoption And Valuation - simplywall.st
Assessing Illumina (ILMN) Valuation After Recent Share Price Rebound And Longer Term Volatility - Yahoo Finance
Illumina (ILMN) Chief Legal Officer sells 1,336 common shares in open market - Stock Titan
Illumina launches TruPath Genome, setting a new standard in genomic insight - Investing News Network
Illumina Launches TruPath Genome Workflow Solution - marketscreener.com
Illumina's TruPath Genome offers rapid whole genome testing for rare disease - Stock Titan
NovaSeq X Series innovation roadmap - Illumina
8,500 Shares in Illumina, Inc. $ILMN Purchased by Monetta Financial Services Inc. - MarketBeat
Next Generation Sequencing Market Competitive Landscape - GlobeNewswire
Illumina, Inc. $ILMN Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Illumina unveils NovaSeq X upgrades with 40% output increase - Investing.com Australia
Illumina, Inc. (ILMN) Stock Analysis: Exploring a 15.62% Potential Upside in the Genomics Sector - DirectorsTalk Interviews
Faster DNA decoding: Illumina’s NovaSeq X gets 40% more data, higher accuracy - Stock Titan
Illumina Beat Q4 Earnings and Closed a $350M Acquisition. Here’s What Investors Need to Know - TIKR.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):